AACR 2022

Long-Term Benefit Observed With Sotorasib in KRAS-Mutant Non-Small Cell Lung Cancer

The 2-year overall survival rate was 32.5%.

Recurrent DCIS Not Always Related to Primary Tumor

Researchers found that, in 18% of recurrences, the new tumor was molecularly unrelated to the original tumor.

Patterns of Resistance to CAR-T Therapy in Patients With Acute Lymphoblastic Leukemia

Researchers sought to determine gene regulation patterns that may help predict response to CAR-T therapy in patients with acute lymphoblastic leukemia.

Racial Disparities Noted in Treatment With Bone-Modifying Agents Among Patients With Multiple Myeloma

Researchers sought to determine if there are racial disparities in treatment with bone-modifying agents for patients with multiple myeloma.

CoVac-1 Induces T-Cell Responses in Patients With B-Cell Deficiencies

CoVac-1, a peptide-based COVID-19 vaccine, induced T-cell responses in patients with B-cell deficiencies.

Risks for Relapse Revealed in Multiethnic Study of Patients With Acute Lymphoblastic Leukemia

Researchers sought to determine risk factors for relapse in patients with ALL.

Biomarkers May Help Guide Treatment in Cancer Patients With COVID-19

Three biomarkers were associated with prognosis after COVID-19 treatment.

Predictors of Mortality During Hospital Stays in Patients With Multiple Myeloma

Researchers sought to determine the predictors of mortality during hospital stays in patients with multiple myeloma.

Combo Appears Effective After Anti-PD-1 Failure in Advanced Melanoma

Ipilimumab plus nivolumab demonstrated efficacy in a phase 2 trial of patients with advanced melanoma who failed prior anti-PD-1 therapy.

Toripalimab-Chemo Dubbed New Standard Care for Advanced Nasopharyngeal Carcinoma

Adding toripalimab to standard chemotherapy extended progression-free survival by 13.2 months.

Adebrelimab Improves PFS, OS in Extensive-Stage Small Cell Lung Cancer

Adding adebrelimab to chemotherapy nearly doubled the 2-year overall survival rate and more than tripled the 1-year progression-free survival rate.

Canakinumab Provides No Benefit in Advanced Non-Small Cell Lung Cancer

Canakinumab did not improve response rates, progression-free survival, or overall survival.

Neoadjuvant Nivolumab Plus Chemo Deemed New Standard Care for Resectable NSCLC

Adding nivolumab to chemotherapy improved the pathologic complete response rate and prolonged event-free survival.

Pandemic Exacerbates Disparities in Outcomes for Pediatric Cancer Patients

Pediatric cancer patients in low- and middle-income countries had a nearly 16-fold higher risk of all-cause mortality within 30 days of presentation, when compared with their counterparts in high-income countries.

RACE Act Increases Required Pediatric Studies for Cancer Drugs

In the year before the RACE Act was implemented, none of the approved therapies required pediatric study, but 92% of them had a mechanism of action that would necessitate pediatric studies under the RACE Act.

Assay-Guided Therapy Improves Survival in High-Grade Glioma

Patients who received treatment selected by the ChemoID assay had superior progression-free survival and overall survival.

AI Model Uses EHR Data to Predict Risk of Pancreatic Cancer

AI models could enable earlier detection of pancreatic cancer and improve treatment options for patients, according to researchers.